Increased CSF F2-isoprostane concentration in probable AD

被引:202
作者
Montine, TJ
Beal, MF
Cudkowicz, ME
O'Donnell, H
Margolin, RA
McFarland, L
Bachrach, AF
Zackert, WE
Roberts, LJ
Morrow, JD
机构
[1] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Med Ctr, Dept Psychiat, Nashville, TN 37232 USA
[5] Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA
[6] Massachusetts Gen Hosp, Dept Neurol, Cambridge, MA USA
关键词
D O I
10.1212/WNL.52.3.562
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To quantify F-2-isoprostane levels in CSF obtained from the lumbar cistern of patients with AD, ALS, and controls. Bachground: Studies of human postmortem tissue and experimental models have suggested a role for oxidative damage in the pathogenesis of several neurodegenerative diseases, especially AD and ALS. F-2-isoprostanes are exclusive products of free-radical-mediated peroxidation of arachidonic acid that have been widely used as quantitative biomarkers of lipid peroxidation in vivo in humans. Recently, we showed that F-2-isoprostane concentrations are significantly elevated in CSF obtained postmortem from the lateral ventricles of patients with definite AD compared with controls. Methods: F-2-isoprostanes were quantified by gas chromatography/negative ion chemical ionization mass spectrometry. Results: CSF F-2-isoprostanes were increased significantly in patients with probable AD, but not in ALS patients, compared with controls. Conclusions: Increased CSF F-2-isoprostanes are not an inevitable consequence of neurodegeneration and suggest that increased brain oxidative damage may occur early in the course of AD.
引用
收藏
页码:562 / 565
页数:4
相关论文
共 12 条
[1]  
Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109
[2]   AGING, ENERGY, AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES [J].
BEAL, MF .
ANNALS OF NEUROLOGY, 1995, 38 (03) :357-366
[3]  
Ferrante RJ, 1997, J NEUROCHEM, V69, P2064
[4]  
GUTTERIDGE JMC, 1986, FREE RADICALS AGING, P99
[5]  
HARMAN D, 1986, FREE RADICALS AGING, P99
[6]   Oxidative stress hypothesis in Alzheimer's disease [J].
Markesbery, WR .
FREE RADICAL BIOLOGY AND MEDICINE, 1997, 23 (01) :134-147
[7]  
MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
[8]   Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease [J].
Montine, TJ ;
Markesbery, WR ;
Morrow, JD ;
Roberts, LJ .
ANNALS OF NEUROLOGY, 1998, 44 (03) :410-413
[9]   The isoprostanes: Unique bioactive products of lipid peroxidation [J].
Morrow, JD ;
Roberts, LJ .
PROGRESS IN LIPID RESEARCH, 1997, 36 (01) :1-21
[10]   RATE OF PROGRESSION OF ALZHEIMERS-DISEASE [J].
ORTOF, E ;
CRYSTAL, HA .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1989, 37 (06) :511-514